Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gan and Lee PharmaceuticalsSHSE:603087 -2.27%90 Gross Margin % is 73.84% as of Jun. 2026, which is 18% below its 10-year median of 89.82. GuruFocus rates SHSE:603087 with a GF Score™ of 90/100 and a GF Value™ of ¥73.00 (Fairly Valued). The stock has 5 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Gan and Lee Pharmaceuticals ranks better than 85.07% on this metric.
SHSE:603087's Gross Margin % is ranked better than 85.07% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 52.44
vs SHSE:603087: 74.73
Gan and Lee Pharmaceuticals had a gross margin of 73.84% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Gan and Lee Pharmaceuticals (SHSE:603087) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Gan and Lee Pharmaceuticals had a gross margin of 73.84% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Gan and Lee Pharmaceuticals Gross Margin % Related Terms
Gan and Lee Pharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603087 vs ISRG, BDX, RMD: Gross Margin % Comparison
For the Medical Instruments & Supplies subindustry, Gan and Lee Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gan and Lee Pharmaceuticals Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gan and Lee Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Gan and Lee Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Gan and Lee Pharmaceuticals (SHSE:603087) has a Gross Margin % of 73.84% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Gan and Lee Pharmaceuticals and its competitors. This is 18% below median its historical median of 89.82. Over the past decade, Gan and Lee Pharmaceuticals' Gross Margin % has ranged from 73.26 to 92.13. According to the industry distribution chart, Gan and Lee Pharmaceuticals ranks #120 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 14.9%.
Is Gan and Lee Pharmaceuticals' Gross Margin % too high?
Gan and Lee Pharmaceuticals' current Gross Margin % of 73.84% is 18% below median its 10-year median of 89.82. Over the past 10 years, this metric has ranged from a low of 73.26 to a high of 92.13. The Medical Devices & Instruments industry median Gross Margin % is 52.44. Gan and Lee Pharmaceuticals' value of 73.84% is 40.8% above this industry median. Based on the distribution chart, Gan and Lee Pharmaceuticals ranks #120 out of 804 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Gan and Lee Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gan and Lee Pharmaceuticals' Gross Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Gan and Lee Pharmaceuticals ranks #120 out of 804 companies for Gross Margin %. This places Gan and Lee Pharmaceuticals in the top 15% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 52.44. Gan and Lee Pharmaceuticals' value of 73.84% is 40.8% above this benchmark. Historically, Gan and Lee Pharmaceuticals' own Gross Margin % has ranged from 73.26 to 92.13 over the past decade. While the company's 10-year median is 89.82 vs. the industry median of 52.44, Gan and Lee Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.44, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gan and Lee Pharmaceuticals's current Gross Margin % of 73.84% is 40.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Gan and Lee Pharmaceuticals and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gan and Lee Pharmaceuticals's current Gross Margin % is 73.84%, which is 18% below median its own 10-year median of 89.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gan and Lee Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals (SHSE:603087) is currently considered Fairly Valued. The stock's GF Value™ is ¥73.00, compared to a current price of ¥66.34 — trading 9.1% below its estimated fair value. The current Gross Margin % is 73.84%, which is 18% below median its 10-year median of 89.82 and 40.8% above the Medical Devices & Instruments industry median of 52.44. Gan and Lee Pharmaceuticals' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Gan and Lee Pharmaceuticals (SHSE:603087), the current Gross Margin % is 73.84% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gan and Lee Pharmaceuticals (SHSE:603087) Overvalued in 2026?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals stock appears to be undervalued.
The current stock price of ¥66.34 is trading 9.1% below its estimated GF Value™ of ¥73.00.
GuruFocus considers Gan and Lee Pharmaceuticals to be Fairly Valued.
Key valuation signals for SHSE:603087:
Gross Margin %: 73.84% (18% below median its 10-year median of 89.82)
GF Value™: ¥73.00 vs. price of ¥66.34 (9.1% below fair value)
Industry Position: 40.8% above the Medical Devices & Instruments median (#120 of 804)
No single metric tells the full story. See the SHSE:603087 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603087 has been successfully added to your 
